Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 7:15:31-37.
doi: 10.1016/j.ctro.2018.11.002. eCollection 2019 Feb.

Radiation for ETMR: Literature review and case series of patients treated with proton therapy

Affiliations

Radiation for ETMR: Literature review and case series of patients treated with proton therapy

Sergio Jaramillo et al. Clin Transl Radiat Oncol. .

Abstract

Background and purpose: Embryonal tumors with multilayered rosettes (ETMRs) are aggressive tumors that typically occur in young children. Radiation is often deferred or delayed for these patients due to late effects; proton therapy may mitigate some of these concerns. This study reviews the role of radiation in ETMR and describes initial results with proton therapy.

Materials and methods: Records of patients with embryonal tumor with abundant neuropil and true rosettes (ETANTR), medulloepithelioma (MEP), and ependymoblastoma (EPL) treated with proton therapy at our institution were retrospectively reviewed. A literature review of cases of CNS ETANTR, MEP, and EPL published since 1990 was also conducted.

Results: Seven patients were treated with proton therapy. Their median age at diagnosis was 33 months (range 10-57 months) and their median age at radiation start was 42 months (range 17-58 months). Their median overall survival (OS) was 16 months (range 8-64 months), with three patients surviving 36 months or longer. Five patients had disease progression prior to starting radiation; all 5 of these patients failed in the tumor bed. A search of the literature identified 204 cases of ETMR with a median OS of 10 months (range 0.03-161 months). Median OS of 18 long-term survivors (≥36 months) in the literature was 77 months (range 37-184 months). Of these 18 long-term survivors, 17 (94%) received radiotherapy as part of their initial treatment; 14 of them were treated with craniospinal irradiation.

Conclusions: Outcomes of patients with ETMR treated with proton therapy are encouraging compared to historical results. Further study of this rare tumor is warranted to better define the role of radiotherapy.

Keywords: ETANTR; ETMR; Ependymoblastoma; Medulloepithelioma; Pediatric; Proton; Radiation.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eberhart C.G., Brat D.J., Cohen K.J., Burger P.C. Pediatric neuroblastic brain tumors containing abundant neuropil and true rosettes. Pediatr Dev Pathol. 2000;3:346–352. - PubMed
    1. Korshunov A., Remke M., Gessi M., Ryzhova M., Hielscher T., Witt H. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol. 2010;120:253–260. - PubMed
    1. Korshunov A., Ryzhova M., Jones D.T.W., Northcott P.A., van Sluis P., Volckmann R. LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR) Acta Neuropathol. 2012;124:875–881. - PMC - PubMed
    1. Li M., Lee K.F., Lu Y., Clarke I., Shih D., Eberhart C. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009;16:533–546. - PMC - PubMed
    1. Pfister S., Remke M., Castoldi M., Bai A.H.C., Muckenthaler M.U., Kulozik A. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol. 2009;117:457–464. - PubMed

LinkOut - more resources